ArticleMicroorganisms2020
Soy Metabolism by Gut Microbiota from Patients with Precancerous Intestinal Lesions.
Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Gut microbial metabolites in inflammatory bowel disease: immunological mechanisms regulating Treg/Th17 balance and therapeutic potential.Frontiers in immunology · 2026Review
- Therapeutic Efficacy of Soy-Derived Bioactives: A Systematic Review of Nutritional Potency, Bioactive Therapeutics, and Clinical Biomarker Modulation.Foods (Basel, Switzerland) · 2025Review
- Establishment and validation of a clinical prediction model for colorectal adenoma risk factors.Oncology letters · 2025Article
- Bifidobacterium lactis ameliorates AOM/DSS-induced inflammation, dysbiosis, and colonic precancerous lesions.Applied microbiology and biotechnology · 2025Article
- Interplay Between Dietary Phytochemicals and Gut Microbiota in Colorectal Cancer: Future Directions and Considerations.Journal of nutrition and metabolism · 2025Review
- Current View on How Human Gut Microbiota Mediate Metabolic and Pharmacological Activity ofEndocrine, metabolic & immune disorders drug targets · 2024Article
- Oral microbiota in human health and disease: A perspective.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Microbiota revolution: How gut microbes regulate our lives.World journal of gastroenterology · 2023Review
- An Overview of the Microbiota of the Human Urinary Tract in Health and Disease: Current Issues and Perspectives.Life (Basel, Switzerland) · 2023Review
- The Crosstalk between Gut Microbiota and Nervous System: A Bidirectional Interaction between Microorganisms and Metabolome.International journal of molecular sciences · 2023Review
- Pretreatment withFrontiers in microbiology · 2023Article
- The Connection Between Physical Exercise and Gut Microbiota: Implications for Competitive Sports Athletes.Sports medicine (Auckland, N.Z.) · 2022Review
- Biomolecular Mechanisms of Autoimmune Diseases and Their Relationship with the Resident Microbiota: Friend or Foe?Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Review
- The Intestinal Microbiota May Be a Potential Theranostic Tool for Personalized Medicine.Journal of personalized medicine · 2022Review
- The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants.Antioxidants (Basel, Switzerland) · 2021Review
- A Correlation Study of Prognostic Risk Prediction for Colorectal Cancer Based on Autophagy Signature Genes.Frontiers in oncology · 2021Article
- Microbiota and Obesity: Where Are We Now?Biology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundColorectal cancer (CRC) requires the presence of a variety of factors predisposing a tumorigenic milieu. Excluding familial clustering and hereditary CRC syndromes, the development of sporadic CRC from precancerous lesions is influenced by tissue inflammation, modulation of intestinal immunity, hormones, dietary habits and gut microbiota composition. As concerning the last two aspects, the intestinal presence of equol, the most biologically active metabolite of the soy isoflavone daidzein and the presence of a genetic determinant of gut microbiota able to metabolize daidzein, seem to lower the CRC risk. It has been hypothesized that the anaerobic microorganisms of the
aimTo evaluate the presence of (i) anaerobic gut microbiota and (ii) the urinary levels of soy isoflavones (daidzein, genistein and equol) in patients with and without precancerous lesions, challenged with a daidzein-rich soy extract.
methodsConsecutive subjects undergoing colonoscopy participated to the study. Feces were collected from all patients one week before colonoscopy for gut microbiota studies. After the endoscopy examination and the histological evaluation, 40 subjects, 20 with sporadic colorectal adenomas (SCA/P group) and 20 without proliferative lesions (control group) were enrolled for the study. Urine levels of soy isoflavones daidzein, genistein and their metabolite equol, were determined by high performance liquid chromatographic (HPLC) analysis and gut microbiota analysis was performed by Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS) procedure.
resultsSeventeen different bacterial species were identified in the fecal samples of the forty subjects participating to the study. Ten bacterial species resulted anaerobic Gram-negative bacteria, all belonging to the
conclusionsOur results suggest that the presence of anaerobic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.